Roivant Sciences Ltd.

NASDAQ (USD): Roivant Sciences Ltd. (ROIV)

Last Price

10.73

Today's Change

-0.10 (0.92%)

Day's Change

10.71 - 11.15

Trading Volume

9,499,993

Profile
ROIV

Exchange:  NASDAQ Global Market NASDAQ Global Market

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Mr. Matthew Gline Mr. Matthew Gline

Full Time Employees:  904 904

IPO Date:  2020-12-08 2020-12-08

CIK:  0001635088 0001635088

ISIN:  BMG762791017 BMG762791017

CUSIP:  G76279101 G76279101

Beta:  1.30 1.30

Last Dividend:  0.00 0.00

Dcf Diff:  14.35 14.35

Dcf:  -3.62 -3.62

Description

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Address

11-12 St. James’s Square,
London, SW1Y 4LB, GB

44 2074 003 347

http://roivant.com

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment